Comparative Pharmacology
Head-to-head clinical analysis: OMNIPAQUE 240 versus UROVIST CYSTO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OMNIPAQUE 240 versus UROVIST CYSTO.
OMNIPAQUE 240 vs UROVIST CYSTO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodinated radiocontrast agent that attenuates X-rays due to high atomic number of iodine, enhancing vascular and tissue contrast during imaging procedures. It distributes in extracellular fluid and is excreted unchanged by glomerular filtration.
Urovist Cysto is a radiocontrast agent containing diatrizoate meglumine and diatrizoate sodium. It provides radiographic visualization of the urinary tract by attenuating X-rays due to its iodine content. It is not systemically absorbed when used intravesically; local contrast enhancement occurs through physical properties.
Intravenous administration: 50-200 mL (12-48 g iodine) of OMNIPAQUE 240 (240 mg iodine/mL) as a single dose, adjusted for procedure and patient size.
Instillation of 50 mL of a 0.3% solution intravesically, retained for 10 minutes, for cystography.
None Documented
None Documented
Terminal half-life approximately 1-2 hours in normal renal function; prolonged to 20-40 hours in severe renal impairment (CrCl <30 mL/min), necessitating dose adjustment
Terminal elimination half-life is approximately 2 hours in patients with normal renal function; may be prolonged in renal impairment.
Primarily renal (glomerular filtration, no tubular reabsorption); >95% excreted unchanged in urine within 24 hours; <5% biliary/fecal
Primarily renal excretion as unchanged drug (approximately 85-90% within 24 hours); minor biliary/fecal elimination (<5%).
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent